Head and Neck Cancer
Conditions
Brief summary
This phase II, open-label, randomized study will evaluate the efficacy and safety of MEHD7945A versus cetuximab in patients with recurrent/metastatic squamous cell carcinoma of the head and neck who have progressed during or following platinum-based chemotherapy. Patients will be randomized to receive either MEHD7945A 1100 mg intravenously (iv) every 2 weeks or cetuximab 400 mg/m2 iv loading dose followed by 250 mg/m2 iv weekly. Patients treated with cetuximab (Arm B) may cross-over to MEHD7945A (Arm A) upon central confirmation of progressive disease and upon meeting eligibility criteria. Anticipated time on study treatment is until disease progression or intolerable toxicity occurs.
Interventions
DRUGMEHD7945A
1100 mg iv every 2 weeks
DRUGcetuximab
400 mg/m2 iv loading dose, followed by 250 mg/m2 weekly
Sponsors
Genentech, Inc.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Adult patients, \>/= 18 years of age * Histologically confirmed Stage III or IV recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) * Progressive disease on or after first-line platinum-based chemotherapy regimen for R/M SCCHN (maximum of 6 cycles) * No more than one platinum-based chemotherapy regimen for R/M SCCHN is allowed * Prior platinum-based treatment as definitive chemo/radiotherapy for locally advanced disease is allowed if completed/terminated \>/= 6 months before the platinum-based regimen for R/M SCCHN * Consent to provide archival tumor tissue for biomarker testing * Measurable disease per RECIST v1.1 * ECOG performance status of 0, 1 or 2 * Adequate hematologic, renal and liver function
Exclusion criteria
* Nasopharyngeal cancer * Prior treatment with an investigational or approved agent for the purpose of inhibiting HER family members * This includes but is not limited to cetuximab, panitumumab, erlotinib, geftinib, and lapatinib * Prior treatment with an EGFR inhibitor is allowed if it was administered as part of definitive therapy for locally advanced disease and completed \>/=1 year before study enrollment * Leptomeningeal disease as the only manifestation of the current malignancy * Active infection requiring iv antibiotics * Active autoimmune disease that is not controlled by non-steroidal anti-inflammatory drugs * Current severe, uncontrolled systemic disease (e.g. clinically significant cardiovascular, pulmonary, or metabolic disease; wound healing disorders; ulcers; bone fractures) * History of heart failure or serious cardiac arrhythmia * History of myocardial infarction within 6 months of Cycle 1, Day 1 * Clinically significant liver disease, including active viral, alcoholic or other hepatitis, cirrhosis, or current alcohol abuse * HIV infection * Primary central nervous system (CNS) malignancy or untreated/active CNS metastases (progressing or requiring anticonvulsants or corticosteroids for symptomatic control) * Pregnant or lactating women * Malignancies other than SCCHN within 5 years prior to randomization, with the exception of adequately treated basal or squamous cell skin cancer and carcinoma in situ of the cervix
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression-free survival (tumor assessments according to RECIST criteria) | approximately 24 months |
Secondary
| Measure | Time frame |
|---|---|
| Disease control: complete response, partial response or stable disease | approximately 24 months |
| Duration of objective response | approximately 24 months |
| Time to disease progression | approximately 24 months |
| Objective response: complete response or partial response | approximately 24 months |
| Safety: Incidence of adverse events | approximately 24 months |
| Pharmacokinetics: Cmax/Cmin | Pre-dose and 30 min after end of infusion on Day 1 of Cycles 1, 2, 3, and 4, and at treatment completion |
| Immunogenicity: anti-MEHD7945A levels | Pre-dose on Day 1 of Cycles 1 and 4, and at treatment completion |
| Overall survival | approximately 24 months |
Countries
Australia, Belgium, Bulgaria, France, Germany, Hungary, Italy, Romania, Spain, United Kingdom, United States
Outcome results
None listed